A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

Lecanemab is licensed for use in the UK but the spending watchdog deemed the benefits shown in clinical trials were 'too ...

The spending watchdog deemed the drug's benefits 'too small' to justify the cost of making it available on the NHS ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

Q: I’m 68 and overweight by 45 pounds. Now that GLP-1s are going to be covered by Medicare, I think I will add that to my ...

Home Instead chief executive Martin Jones said: “Dementia has now eclipsed cancer as our greatest health fear for the future.

Q: I'm feeling a little fuzzy-brained and am debating whether to get tested for Alzheimer's. Do you think it's a good idea? -- Cassie R., Knoxville, Tennessee ...

Since the landmark approvals of lecanemab and donanemab, anti-amyloid immunotherapy has marked a paradigm shift in ...

Q: I’m feeling a little fuzzy-brained and am debating whether to get tested for Alzheimer’s. Do you think it’s a good idea? — ...